T Cell ImmunotherapyOptimizing Trial Design Session I Current Status of Cancer Immunotherapy: Trials, Results, and Challenges Richard P Junghans, PhD, MD Roger Williams Medical Center

First Page		Document Content
Date: 2014-01-09 16:16:13 Molecular biology Prostate cancer Retrovirus Prostate-specific membrane antigen Immunotherapy Cancer immunotherapy Neuroblastoma Lentivirus Medicine Oncology Immune system		T Cell ImmunotherapyOptimizing Trial Design Session I Current Status of Cancer Immunotherapy: Trials, Results, and Challenges Richard P Junghans, PhD, MD Roger Williams Medical Center Add to Reading List Source URL: osp.od.nih.gov Download Document from Source Website File Size: 683,28 KB Share Document on Facebook

	Uncertainty evaluation of image-based tumour control probability models in radiotherapy of prostate cancer using a visual analytic tool DocID: 1vnrm - View Document
	Abstract # 3991 Novel small molecule inhibitor of p300/CBP down-regulates androgen receptor (AR) and c-Myc for the treatment of prostate cancer and beyond CellCentric DocID: 1vi4a - View Document
	Spring 2014 Issue YES TO LIFE YOUR OPTIONS FOR CANCER Dear Friends and Supporters, In the last Newsletter, we told you about our autumn London Seminar on prostate cancer, the first of our DocID: 1v4PI - View Document
	CANINE BLADDER CANCER by Deborah W. Knapp, DVM, Dipl. ACVIM Cancer of the urinary tract in dogs can affect the kidneys, ureters, urinary bladder, prostate, or urethra (see Figure 1). Within the urinary DocID: 1uUAX - View Document
	EDITORIAL Prostate cancer and selective serotonin reuptake inhibitors Alka Aggarwal Aggarwal A. Prostate cancer and selective serotonin reuptake inhibitors.Ann Histol Surg Pathol. 2017;1(1)5. DocID: 1uKru - View Document